post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
Published 6 years ago • 195 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
1:06
dr. cohen discusses the keynote-040 trial in head and neck cancer
-
2:26
sd-101 plus pembrolizumab for hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
3:08
improved survival, toxicity & qol with pembrolizumab in head and neck cancer
-
7:56
keynote-048: progression post next line for r/m hnscc
-
5:34
pembrolizumab for recurrent hnscc
-
11:47
pembrolizumab in hnscc
-
3:35
is there a use for anti-pdl-1 antibodies in recurrent head and neck cancer?
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
0:54
dr. bestvina on the keynote-407 trial in squamous nsclc
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
4:12
nondriver nsclc: adding pembrolizumab to platinum-based chemotherapy
-
5:00
keynote-055:pembrolizumab in hnscc
-
6:55
researcher comment: the keynote-799 trial | salma jabbour
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
2:38
exciting results of the scores trial